| scholarly article | Q13442814 |
| P50 | author | David Wong | Q91719683 |
| P2093 | author name string | David Chia | |
| Fang Wei | |||
| Michael Tu | |||
| P2860 | cites work | The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website | Q24645514 |
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| PCR-based methods for the enrichment of minority alleles and mutations | Q24657701 | ||
| Liquid biopsies: genotyping circulating tumor DNA | Q27010159 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| Double-stranded DNA in exosomes: a novel biomarker in cancer detection | Q28237711 | ||
| Quantitative and sensitive detection of rare mutations using droplet-based microfluidics | Q28238121 | ||
| Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA | Q28239638 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| COSMIC: exploring the world's knowledge of somatic mutations in human cancer | Q29615725 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Isolation and retrieval of circulating tumor cells using centrifugal forces. | Q30535350 | ||
| Detection of p53 and K-ras mutations in sputum of individuals exposed to smoky coal emissions in Xuan Wei County, China | Q31132051 | ||
| Electrochemical sensor for multiplex biomarkers detection | Q33563305 | ||
| Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. | Q33735738 | ||
| Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors | Q33769838 | ||
| Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. | Q33904626 | ||
| The origin of oncogenic mutations: where is the primary damage? | Q33920599 | ||
| Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. | Q33944203 | ||
| Comparison of Sanger sequencing, pyrosequencing, and melting curve analysis for the detection of KRAS mutations: diagnostic and clinical implications | Q33947050 | ||
| Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer | Q34039531 | ||
| A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) | Q34041754 | ||
| Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
| Microfluidic, marker-free isolation of circulating tumor cells from blood samples | Q34263808 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck | Q34287207 | ||
| Liquid biopsy: monitoring cancer-genetics in the blood | Q34356149 | ||
| Tumour heterogeneity in the clinic | Q34372080 | ||
| BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions | Q34540801 | ||
| Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? | Q34577740 | ||
| Electric field directed nucleic acid hybridization on microchips | Q34743812 | ||
| Combining allele-specific fluorescent probes and restriction assay in real-time PCR to achieve SNP scoring beyond allele ratios of 1:1000. | Q34760338 | ||
| A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer | Q34760642 | ||
| KRAS mutation analysis by PCR: a comparison of two methods | Q34876437 | ||
| Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis | Q34903217 | ||
| Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. | Q35127938 | ||
| Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumours of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinica | Q35640506 | ||
| Restriction endonuclease-mediated selective polymerase chain reaction: a novel assay for the detection of K-ras mutations in clinical samples | Q35753312 | ||
| BEAMing up personalized medicine: mutation detection in blood | Q36040951 | ||
| DNA mutation detection and analysis using miniaturized microfluidic systems | Q36344104 | ||
| Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer | Q36431426 | ||
| Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood | Q36497457 | ||
| Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes | Q36616092 | ||
| Low percentage of KRAS mutations revealed by locked nucleic acid polymerase chain reaction: implications for treatment of metastatic colorectal cancer | Q36621776 | ||
| Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy | Q37286893 | ||
| Determining lower limits of detection of digital PCR assays for cancer-related gene mutations | Q37456162 | ||
| Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients | Q37499417 | ||
| Endoscopic ultrasound-guided fine-needle aspiration biopsy and trucut biopsy in gastroenterology - An overview | Q37595056 | ||
| Isolation of circulating tumor cells by dielectrophoresis | Q37693324 | ||
| Extracellular vesicles--vehicles that spread cancer genes | Q37996375 | ||
| Circulating tumor cells: liquid biopsy of cancer | Q38046735 | ||
| Real-time liquid biopsy in cancer patients: fact or fiction? | Q38154437 | ||
| Molecular analysis of circulating tumour cells-biology and biomarkers | Q38180320 | ||
| Mutant p53 in cancer: new functions and therapeutic opportunities | Q38197826 | ||
| Gold-nanoparticle-based colorimetric discrimination of cancer-related point mutations with picomolar sensitivity | Q38315299 | ||
| Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial | Q38385410 | ||
| KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
| Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel | Q38463506 | ||
| Single-point mutation detection in RNA extracts using gold nanoparticles modified with hydrophobic molecular beacon-like structures | Q39027262 | ||
| Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. | Q39378163 | ||
| Detection of DNA mutations by fluorescence resonance energy transfer-based preferential homoduplex formation assay | Q39654439 | ||
| BEAMing and Droplet Digital PCR Analysis of Mutant IDH1 mRNA in Glioma Patient Serum and Cerebrospinal Fluid Extracellular Vesicles. | Q40126434 | ||
| Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. | Q40130589 | ||
| A simple method for detecting single base substitutions and its application to HLA-DPB1 typing | Q40399531 | ||
| Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies | Q41484128 | ||
| Genotypic selection methods for the direct analysis of point mutations | Q41645720 | ||
| Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations | Q41874659 | ||
| Bio/abiotic interface constructed from nanoscale DNA dendrimer and conducting polymer for ultrasensitive biomolecular diagnosis. | Q42944278 | ||
| Challenges in circulating tumour cell research | Q43500645 | ||
| Gold nanoparticles-based biosensing of single nucleotide DNA mutations | Q43908354 | ||
| Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations | Q44980758 | ||
| Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib | Q46504066 | ||
| Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane | Q46696565 | ||
| Next-generation sequencing: methodology and application | Q46756992 | ||
| Toward point-of-care testing for JAK2 V617F mutation on a microchip. | Q51486044 | ||
| DNA mutation detection with chip-based temperature gradient capillary electrophoresis using a slantwise radiative heating system. | Q51578502 | ||
| Achieving differentiation of single-base mutations through hairpin oligonucleotide and electric potential control. | Q51599711 | ||
| Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. | Q51711228 | ||
| Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. | Q54537674 | ||
| Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. | Q54623807 | ||
| Ras oncogene mutations in urine sediments of patients with bladder cancer. | Q54762488 | ||
| Detection of exosomal biomarker by electric field-induced release and measurement (EFIRM). | Q55358450 | ||
| High-throughput oncogene mutation profiling in human cancer | Q57693480 | ||
| Electric-field assisted immobilization and hybridization of DNA oligomers on thin-film microchips | Q58853392 | ||
| Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis | Q71896504 | ||
| Enrichment methods for mutation detection | Q73808619 | ||
| Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients | Q74020294 | ||
| P433 | issue | 2 | |
| P921 | main subject | biopsy | Q179991 |
| P304 | page(s) | 393-402 | |
| P577 | publication date | 2015-12-08 | |
| P1433 | published in | Analyst | Q969812 |
| P1476 | title | Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB) | |
| P478 | volume | 141 |
| Q49502117 | Advances in liquid biopsy on-chip for cancer management: Technologies, biomarkers, and clinical analysis. |
| Q58544279 | Applications of Nanomaterials for Immunosensing |
| Q61798225 | Digital polymerase chain reaction for detecting c-MYC copy number gain in tissue and cell-free plasma samples of colorectal cancer patients |
| Q46630766 | Electric Field-Induced Disruption and Releasing Viable Content from Extracellular Vesicles. |
| Q28069566 | Emerging technologies for salivaomics in cancer detection |
| Q38749038 | Gastric cancer management: Kinases as a target therapy |
| Q52560940 | High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma. |
| Q39142265 | Liquid Biopsy for Cancer: Circulating Tumor Cells, Circulating Free DNA or Exosomes? |
| Q90473208 | Lnc-PCDH9-13:1 Is a Hypersensitive and Specific Biomarker for Early Hepatocellular Carcinoma |
| Q36188885 | Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing |
| Q58790057 | Promising clinical application of ctDNA in evaluating immunotherapy efficacy |
| Q55009692 | Update on the types and usage of liquid biopsies in the clinical setting: a systematic review. |
Search more.